EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-6.19%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.09B
AUM Growth
+$1.09B
(-9.9%)
Cap. Flow
-$52.6M
Cap. Flow
% of AUM
-4.84%
Top 10 Holdings %
Top 10 Hldgs %
50.97%
Holding
109
New
9
Increased
26
Reduced
34
Closed
23
Top Buys
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$39.1M |
| 2 |
GSK
GSK
|
$30.5M |
| 3 |
Masimo
MASI
|
$30.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$17.3M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
$16.8M |
Top Sells
| 1 |
McKesson
MCK
|
$25.7M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$23.5M |
| 3 |
United Therapeutics
UTHR
|
$17.9M |
| 4 |
Envista
NVST
|
$13.6M |
| 5 |
AstraZeneca
AZN
|
$13.5M |
Sector Composition
| 1 | Healthcare | 94.41% |
| 2 | Industrials | 3.35% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Community Health Systems
CYH
$387M
| $84.6M | 6.5% | 7,126,711 +737,173 | +12% | +$8.75M |
|
|
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $76.4M | 5.87% | 644,666 +329,537 | +105% | +$39.1M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $64.2M | 4.93% | 609,939 -223,811 | -27% | -$23.5M |
|
|
4
GSK
GSK
$79.9B
| $55.5M | 4.26% | 1,259,162 +691,957 | +122% | +$30.5M |
|
|
5
United Therapeutics
UTHR
$13.8B
| $52.4M | 4.03% | 292,234 -99,686 | -25% | -$17.9M |
|
|
6
AstraZeneca
AZN
$248B
| $49.4M | 3.8% | 745,263 -203,961 | -21% | -$13.5M |
|
7
Ascendis Pharma
ASND
$11.8B
| $49M | 3.76% | 417,172 +13,494 | +3% | +$1.58M |
|
8
Danaher
DHR
$147B
| $46.9M | 3.6% | 159,768 -10,285 | -6% | -$3.02M |
|
|
9
Teva Pharmaceuticals
TEVA
$21.1B
| $38.9M | 2.99% | 4,143,602 +1,842,104 | +80% | +$17.3M |
|
|
RCM
10
DELISTED
R1 RCM Inc. Common Stock
RCM
| $36.4M | 2.8% | 1,361,506 +628,374 | +86% | +$16.8M |
|
11
Avantor
AVTR
$9.18B
| $33.7M | 2.58% | 995,232 -130,233 | -12% | -$4.4M |
|
|
12
Masimo
MASI
$7.59B
| $30.4M | 2.34% | +208,970 | New | +$30.4M |
|
|
AMRN
13
Amarin Corp
AMRN
$311M
| $29.5M | 2.27% | 8,980,145 -1,593,157 | -15% | -$5.24M |
|
14
HCA Healthcare
HCA
$94.5B
| $27.9M | 2.14% | 111,440 +62,346 | +127% | +$15.6M |
|
|
15
Envista
NVST
$3.52B
| $27.7M | 2.13% | 569,351 -279,947 | -33% | -$13.6M |
|
16
Amneal Pharmaceuticals
AMRX
$3B
| $22.9M | 1.76% | 5,491,497 -949,075 | -15% | -$3.96M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $21.7M | 1.66% | 636,453 +43,975 | +7% | +$1.5M |
|
18
ARK Genomic Revolution ETF
ARKG
$1.04B
| $21.6M | 1.66% | 470,506 -193,978 | -29% | -$8.91M |
|
19
Fate Therapeutics
FATE
$120M
| $17.7M | 1.36% | 456,059 +201,269 | +79% | +$7.8M |
|
20
Biogen
BIIB
$19.4B
| $16.4M | 1.26% | 78,003 +44,962 | +136% | +$9.47M |
|
|
21
McKesson
MCK
$85.4B
| $16.1M | 1.23% | 52,375 -83,736 | -62% | -$25.7M |
|
22
Elevance Health
ELV
$71.8B
| $15.9M | 1.22% | 32,451 -1,843 | -5% | -$905K |
|
23
DexCom
DXCM
$29.5B
| $14.5M | 1.12% | 28,404 +22,003 | +344% | +$11.3M |
|
24
Guardant Health
GH
$8.41B
| $14.1M | 1.08% | 213,203 +112,869 | +112% | +$7.48M |
|
25
IQVIA
IQV
$32.4B
| $13.8M | 1.06% | 59,570 +34,952 | +142% | +$8.08M |
|